MetaCap

Circle8 Group (CIRC) vs Harvard Bioscience (HBIO)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Harvard Bioscience (HBIO) has outperformed Circle8 Group (CIRC) over the past year, gaining 37.5% versus a loss of 94.4%. Over five years, HBIO leads with a -87.4% price change compared with -99.9% for CIRC. Harvard Bioscience is the larger company by market cap ($39.6 million vs $16.0 million), about 2.5 times the size, while Circle8 Group is growing revenue faster (-1.5% vs -8.1%).

Circle8 Group converts more of its revenue into profit, with a net margin of -13.6% versus -65.5%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CIRC-94.44%HBIO+37.46%
+93%-5%-103%
Nov 21, 20251 yearNov 20, 2026
CIRC-99.88%HBIO-88.36%
+5%-50%-105%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CIRC versus HBIO key metrics
MetricCIRCHBIO
Share price$0.1361$8.66
Market cap$15.99M$39.60M
1-day change-12.25%-0.23%
YTD return-89.77%+29.25%
1-year return-94.44%+37.46%
5-year return-99.88%-87.45%
Forward P/E—16.34
EPS (TTM)$-2.14$-2.59
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$435.88M$86.55M
Revenue growth (YoY)-1.52%-8.06%
Net income (latest FY)$-59.43M$-56.70M
Gross margin10.55%57.67%
Operating margin-11.52%-56.13%
Net margin-13.63%-65.51%
52-week high$4.56$10.20
52-week low$0.136$4.00
Distance from 52-week high-97.02%-15.10%
Analyst consensus—none
Avg. price target upside—-13.39%
Average volume1.13M21.82K
Shares outstanding117.49M4.57M
Employees300316
SectorIndustrialsIndustrials
IndustryBiotechnology: Laboratory Analytical InstrumentsBiotechnology: Laboratory Analytical Instruments

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Harvard Bioscience is about 2.5 times larger than Circle8 Group by market value ($39.60M vs $15.99M).
  • HBIO has outperformed CIRC by 131.9 percentage points over the past year.
  • Circle8 Group is more profitable, keeping -13.6 cents of every revenue dollar as net income versus -65.5 cents for Harvard Bioscience.
  • Circle8 Group grew revenue faster in its latest fiscal year (-1.52% vs -8.06%).

About Circle8 Group

CIRC stock →

Circle8 Group, Inc. provides talent management services.

Industrials · Biotechnology: Laboratory Analytical Instruments · 300 employees

About Harvard Bioscience

HBIO stock →

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the Americas, Europe, the Middle East, Africa, Asia, and internationally.

Industrials · Biotechnology: Laboratory Analytical Instruments · 316 employees

CIRC vs HBIO FAQ

Which is bigger, Circle8 Group or Harvard Bioscience?

Harvard Bioscience (HBIO) is larger, with a market capitalization of $39.60M compared with $15.99M for Circle8 Group (CIRC).

Which stock has performed better over the past year, CIRC or HBIO?

HBIO returned +37.46% over the past 12 months, compared with -94.44% for CIRC (price return, excluding dividends). Past performance does not predict future results.

Are Circle8 Group and Harvard Bioscience in the same industry?

Yes. Both are classified in the Biotechnology: Laboratory Analytical Instruments industry within the Industrials sector.

More comparisons